Tracy Staton

Biography for Tracy Staton

Tracy Staton, Senior Editor

Tracy Staton is the editor of FiercePharma and FiercePharmaMarketing. She has been a freelance writer for eight years, but before that served as editor of the Dallas Business Journal, editor of Texas Business magazine, and a senior editor at American Way, the inflight magazine of American Airlines. She is based in Vermont, and can be reached at tracy@fiercemarkets.com or find her on LinkedIn.

Articles by Tracy Staton

Gilead's Sovaldi the latest casualty in India's patent crusade

India's intellectual-property police nixed a key patent on Gilead Sciences' hepatitis C drug Sovaldi, opening the door for cheap generic copies from domestic drugmakers such as Natco Pharma. It's the latest blow to a multinational drugmaker's ambitions in India, which remains one of the fastest-growing drug markets in the world.

Armed with Pegasus win, AstraZeneca targets another sales boost for Brilinta

Soon after CEO Pascal Soriot took over at AstraZeneca in 2012, he declared Brilinta to be a big opportunity for growth. That was a surprise, given the blood thinner's laggardly sales since its 2011 launch. But Soriot put cash on the table to back up his hunch, with plans for big outcomes studies, stepped-up advertising, and an expanded cadre of sales reps.

With hep C price deals made, Express Scripts eyes PCSK9 meds--and then cancer

Now that Express Scripts--and rival CVS Health--have cost-slashing exclusives with hep C drugmakers, the activist PBM says it's ready to take on the forthcoming class of cholesterol-fighters known as PCSK9 inhibitors, too.

Thanks to hep C pricing war, Gilead, AbbVie both score spots on Prime's coverage list

Better late than never? Try better late than early for Prime Therapeutics, which has scored deals on both sets of hepatitis C drugs. As Bloomberg reports, Gilead Sciences and AbbVie each offered prices low enough to justify putting Harvoni and Viekira Pak on its preferred formulary.

JPM: Sanofi touts Toujeo prospects; Celgene eyes 22% sales hike; Valeant amps up DTC, sales hiring

When the JP Morgan Healthcare Conference rolls around, it's always a case of so much news, so little time (and space). So, we're collecting some of the bigger stories here.

Roche bets $1.2B on Foundation Medicine with deal for majority stake

Roche is throwing the full weight of its global rep and more than $1 billion behind Foundation Medicine's ambitious sequencing technology, designed to tailor cancer treatment to particular patients and guide development of new cancer drugs.

Bristol-Myers scores lung cancer survival data on Opdivo as Merck preps for Keytruda filing

Bristol-Myers Squibb and Merck & Co. rolled out some juicy news about their cancer immunotherapies as the JPMorgan Healthcare Conference got into full swing. And the tit-for-tat press releases turned up the spotlight on one of the most closely watched drug match-ups on the market.

UPDATED: Shire CEO extends deal drive with $5.2B NPS Pharma buyout

Shire has snapped up NPS Pharmaceuticals for $5.2 billion, in a deal aimed at beefing up its rare disease portfolio.

How much for docs speaking on Eliquis, Xarelto and Pradaxa? $20M and counting

If you've watched television lately, you know that Pfizer and Bristol-Myers have been spending a lot of money on advertising to back their new anticoagulant, Eliquis. So have rival Boehringer Ingelheim, with its Pradaxa drug, and Bayer and Johnson & Johnson with Xarelto.

Big Pharma threatens to sue U.K. fund as officials nix Novartis, Sanofi and Eisai meds

U.K. officials have decided which drugs to toss off the Cancer Drug Fund, which pays for drugs rejected by cost-effectiveness gatekeepers. Reportedly, Novartis, Sanofi and Eisai treatments are among them.